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Abstract
The complement system is a key driver of neuroinflammation. Activation of complement by all pathways, results in
the formation of the anaphylatoxin C5a and the membrane attack complex (MAC). Both initiate pro-inflammatory
responses which can contribute to neurological disease. In this study, we delineate the specific roles of C5a
receptor signaling and MAC formation during the progression of experimental autoimmune encephalomyelitis
(EAE)-mediated neuroinflammation. MAC inhibition was achieved by subcutaneous administration of an antisense
oligonucleotide specifically targeting murine C6 mRNA (5 mg/kg). The C5a receptor 1 (C5aR1) was inhibited with
the C5a receptor antagonist PMX205 (1.5 mg/kg). Both treatments were administered systemically and started after
disease onset, at the symptomatic phase when lymphocytes are activated. We found that antisense-mediated
knockdown of C6 expression outside the central nervous system prevented relapse of disease by impeding the
activation of parenchymal neuroinflammatory responses, including the Nod-like receptor protein 3 (NLRP3)
inflammasome. Furthermore, C6 antisense-mediated MAC inhibition protected from relapse-induced axonal and
synaptic damage. In contrast, inhibition of C5aR1-mediated inflammation diminished expression of major pro-
inflammatory mediators, but unlike C6 inhibition, it did not stop progression of neurological disability completely.
Our study suggests that MAC is a key driver of neuroinflammation in this model, thereby MAC inhibition might be
a relevant treatment for chronic neuroinflammatory diseases.
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Introduction
Neuroinflammation, or glial-cell propagated inflamma-
tion, is a broad concept describing the immune re-
sponses which are induced by inflammation or
degeneration [43]. Initially considered as ‘bystander
damage’ caused by cell injury, neuroinflammation was
for a long time seen as a reaction to neuronal damage.
This view was recently challenged in the light of
evidence supporting a central role for neuroinflamma-
tion in neurodegenerative diseases. It is now known that
the resident glial cells also have immunoprotective roles
and can recruit peripheral immune cells into the central
nervous system (CNS), if needed. Similar to most im-
mune processes however, deviations from the delicate
balance of homeostasis might prolong or exacerbate
neuroinflammation, which in turn, promotes disease
progression [14].
The complement system is a key component of innate
immunity. Activation of the complement system involves
various components, including C1q, mannan-binding
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lectin, C3 and C5, and has a critical role in the defense
against infections, disposal of dead or dying cells, elimin-
ation of supernumerary synapses during development
and response to ‘danger signals’ whether flagged by auto-
antibodies or recognized as altered-self. All pathways of
complement activation lead to cleavage of the C5 mol-
ecule for generation of the anaphylatoxin C5a, and the
opsonin C5b. C5b and the complement proteins C6
through C9, together form an oligomeric structure called
the membrane attack complex (MAC) [66]. C5a and
MAC have been shown as two major effectors of neuroin-
flammation and degeneration [4, 17, 47, 62, 63, 69, 85].
C5a exerts pronounced pro-inflammatory activity primar-
ily through the G-coupled receptor for C5a (C5aR1) [81].
MAC causes cytolysis [66] or can act as an immune
stimulating factor by promoting the secretion of interleu-
kin 1 beta (IL-1β) via the Nod-like receptor protein 3
(NLRP3) inflammasome, when deposited at sub-lytic
amounts [45, 78].
We propose that the terminal part of the complement
system has a central role in neuroinflammation, driving
degeneration. Because the individual roles of C5a and
MAC in this process are not yet delineated we investi-
gated the explicit effects of C5a and MAC on neuroin-
flammation using selective therapeutic inhibitors.
Previous research on the role of MAC in neuroinflam-
mation was performed under conditions in which MAC
formation was inhibited already before induction of neu-
roinflammation [51, 83]. In these models one cannot
rule out that induction of disease is affected by the defi-
ciency of MAC. Here, we used the chronic relapsing ex-
perimental autoimmune encephalomyelitis (EAE) model
of chronic neuroinflammation [35]. This model is used
to study mechanisms of degeneration [44] and shows
complement activation in the CNS [61]. Inhibition of
the complement cascade was started after full induction
of the disease, when T lymphocytes were activated. In
order to discriminate between C5a- and MAC-mediated
effects we selected the inhibitor PMX205, specific for
the C5a receptor 1 (C5aR1), and the inhibitor RGS1104,
a C6 mRNA antisense oligonucleotide which blocks
MAC formation. PMX205 is a C5aR1 antagonist with
pharmacokinetics that allow inhibition in the CNS [85].
The C6 antisense oligonucleotide is an effective inhibitor
of the C6 mRNA, which is predominantly expressed in
the liver [29]. Preventing production of C6 will effect-
ively deplete the body thus, also prevent generation of
MAC without affecting potential C5a-induced inflamma-
tion or upstream effects.
We show that systemic inhibition of MAC after the
onset of disease prevented relapse completely in mice in-
duced to develop chronic relapsing EAE whereas, inhib-
ition of the C5aR1 mitigated neurological disability.
Notably, MAC inhibition prevented the induction of
major pro-inflammatory pathways within the mouse
CNS, such as the NLRP3 inflammasome pathway. Histo-
logical examination of mouse spinal cords showed that
MAC inhibition protected from relapse-induced axonal
and synaptic damage or loss, two important pathological
components of chronic relapsing EAE. Our data in mice
suggest that MAC is a key contributor to neuroinflam-
mation driving degeneration.
Materials and methods
Animals
Male 7 to 8-week-old Biozzi AB/H mice (n = 52) were
obtained from Harlan (Bicester, U.K.) and housed indi-
vidually in cages, at room temperature (RT), on a 12-h
light: 12-h dark cycle. Animals weighed, on average, 26.
93 ± 0.33 g at the beginning of the study. They were kept
for at least 1 week before the start of the experiments.
They were allowed free access to food and water for the
entire duration of the study and provided with wetted
mash as necessary. Animals were monitored for micro-
biological status according to the Federation of Euro-
pean Laboratory Animal Science Associations (FELASA)
recommendations. All experiments were approved by
the Academic Medical Center Animal Ethics Committee
and complied with the Dutch national policy on humane
care and the use of laboratory animals.
Induction and clinical scoring of chronic relapsing EAE
Disease was induced in 8–12-week-old male Biozzi AB/
H mice by subcutaneous injection into the flank, at both
right and left sides, of 0.3 ml of a sonicated emulsion
consisting of syngeneic Biozzi AB/H spinal cord hom-
ogenate (SCH) emulsified in complete Freund’s adjuvant
(Sigma-Aldrich, St Louis, MO, USA), on days 0, 7, and
of an emulsion consisting of SCH in incomplete Freund’s
adjuvant (Sigma-Aldrich) on day 24, as previously de-
scribed [5, 35]. Each animal received 1 mg of SCH and
60 μg mycobacteria [Mycobacterium tuberculosis H37Ra,
Mycobacterium butyricum (4:1); Difco, BD Biosciences,
San Jose, CA, USA] per injection [5, 35]. Body weight
and clinical signs were assessed daily, as previously de-
scribed [61], using the following five-point scoring sys-
tem: 0, normal; 1, loss of tail tone; 2, impaired righting
reflex; 3, partial hind limb paralysis, with 1 limb affected;
4, complete hind limb paralysis, with both limbs af-
fected; and 5, moribund. Severity of clinical disability
was further analyzed by quantitative (q) PCR analysis for
selected immune genes (Additional file 1: Table S1). Re-
mission from the active disease phase was defined as the
resolution of clinical paralysis, weight gain and
stabilization of the neurological deficit. Relapse was de-
fined as an increase in clinical score of at least one point,
development of paresis of the lower limbs and weight
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loss. Results are shown as the mean clinical scores ±
standard error of the mean (SEM).
Generation and administration of complement inhibitors
The C6 Locked Nucleic Acid (LNA) oligonucleotide
(RGS1104, referred to as C6 antisense), blocker of the
complement component C6, was synthesized with phos-
phorothioate backbones and methylated DNA-C (medC)
by Ribotask (Odense, Denmark), on a Mermade 12,
using 2 g NittoPhase (BioAutomation), as previously de-
scribed [17]. Throughout the process, the oligonucleo-
tide constitution was confirmed by MALDI-TOF mass
spectrometry analysis on a Bruker Autoflex using 3-
hydroxypicolinic acid as matrix. The sequence of the C6
antisense oligonucleotide is 5′-AACttgctgggAAT-3′
(LNA in capital letters, DNA in lowercase letters).
C6 antisense (5 mg/kg) was dissolved in phosphate buff-
ered saline (PBS pH 7.4, Life technologies, Bleiswijk, The
Netherlands) and delivered by osmotic pump at a rate of
0.25 μl per hour, over a period of 14 days (Alzet micro-
osmotic pump, model 1002 Cupertino, CA, USA), starting
on day 21 post immunization (p.i.). Phosphorothioate
antisense oligonucleotides as used in these studies have a
well-defined pharmacokinetic profile and biodistribution
[21]. LNA wingmers like RGS1104 are efficiently taken up
by the liver and mediate RNAseH-mediated mRNA cleav-
age. Subcutaneous dosing with an Alzet osmotic mini-
pump at 5 mg/kg/day for 14 days reduced liver C6 mRNA
levels by 75%, whereas systemic C6 protein levels were re-
duced by 80%, as measured 10 days post-end of treatment
(Additional file 2: Figure S1).
PMX205 [hydrocinnamate-(OPdChaWR)], blocker of
C5aR1 [85], synthesized as previously described [47], was
dissolved in distilled water and delivered by
intraperitoneal injection (1.5 mg/kg), daily, starting on day
21 p.i., until the end of the experiment. The dose of
PMX205 was sufficient to block C5aR1 signaling in the
mouse CNS [7, 9]. A validated LC-MS/MS method was
utilised for quantitative determination of PMX205 in
plasma, brain and spinal cord tissue, using an API 3200
(AB SCIENX) mass spectrometer coupled with Agilent
1200 series liquid chromatographic system operated under
multiple reaction mode [47]. The developed LC-MS/MS
method has a limit of detection (LOD) and limit of quanti-
fication (LOQ) of 1.23 ng/ml and 3.73 ng/ml in plasma.
LOD and LOQ in tissue is 1.95 ng/g and 3.28 ng/g.
Experimental groups and tissue processing
Spinal cords from non-treated SCH-immunized Biozzi
AB/H mice (referred to as no drug) were harvested for
histology or RNA sequencing (RNA-seq) at four time
points p.i. corresponding to: i) the initial acute paralytic
attack (17 days p.i., n = 3), ii) the first remission (25 days
p.i., n = 3), iii) the first relapse (38 days p.i., n = 7), and
iv) the post-relapse phase (44 days p.i., n = 4). Spinal
cords of SCH-immunized mice were compared to
adjuvant-only (n = 9) or naïve (n = 3) controls.
To study the effect of C6 antisense on chronic relaps-
ing EAE we collected spinal cords from mice immunized
with SCH and treated with the C6 antisense oligonucleo-
tide on day 38 p.i. (n = 7) and day 44 p.i. (n = 6). Simi-
larly, to study the effect of PMX205 on chronic relapsing
EAE we collected spinal cords from mice immunized
with SCH and treated with the PMX205 drug on day 38
p.i. (n = 6) and day 44 p.i. (n = 4). Spinal cords from no
drug, C6 antisense- and PMX205-treated animals were
compared with each other, also compared with spinal
cords from healthy control mice.
Mice whose spinal columns were harvested for RNA
isolation and RNA-seq, were anesthetized and intracardi-
ally perfused with PBS. The spinal columns were excised
and dissected into cervical, thoracic and lumbar regions,
separately snap frozen. The frozen tissue was homoge-
nized in TRIzol reagent (Invitrogen, Life Technologies,
Carlsbad, CA, USA), and RNA was purified according to
the manufacturer’s protocol. The concentration and qual-
ity of RNA were confirmed using a QuBit (Thermo Fisher
Scientific, Waltham, MA USA) and a BioAnalyzer 2100
(Agilent, Santa Clara, CA, USA), respectively. All RNA
RIN values were higher than 7.4.
Mice whose spinal columns were harvested for hist-
ology were anesthetized and intracardially perfused with
PBS, followed by 4% paraformaldehyde. The spinal col-
umns were excised and dissected into cervical, thoracic
and lumbar regions; each region was further cut in two
pieces and separately kept in formalin or glutaraldehyde
for standard embedding in paraffin or epon, respectively.
Elisa
Blood was collected from all mice (n = 52) in tubes
coated with ethylenediaminetetraacetic acid (EDTA, Sar-
stedt, Nümbrecht, Germany) to measure serum levels of
C6. The serum was separated by centrifugation twice at
5000 g for 10 min at 4 °C and the supernatant was
pooled and stored at -80 °C. ELISA to detect C6 in the
mouse serum was performed according to a standard
published protocol [40].
Quantitative (q) PCR
Liver was collected from all mice (n = 52) and immedi-
ately placed into RNA later, according to manufacturer’s
instructions (Ambion, Bleiswijk, The Netherlands), to
determine mRNA levels of C6. Total RNA was extracted
from liver tissue using TriPure (Roche Nederland BV,
Woerden, The Netherlands) and chloroform for phase
separation and isopropanol precipitation. For the reverse
transcription reaction, 0.5 μg RNA was mixed with
125 pmol/ml OligodT12-VN and denatured for 5 min at
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65 °C. cDNA was synthesized using SuperScriptIII re-
verse transcriptase (Invitrogen) and incubating at 50 °C
for 1 h. Quantification of RNA was done on a LightCy-
cler 480 (Roche) with the Universal probe system
(Roche). Hypoxanthine phosphoribosyl transferase was
used as reference gene. The primers used are indicated
in (Additional file 1: Table S2). qPCR was performed ac-
cording to manufacturer’s instructions (Roche). Tripli-
cates were used for each cDNA tested. Data were
analyzed using the advanced relative quantification mod-
ule in the LightCycler 480 software (Roche). qPCR was
also performed on samples collected from homogenized
spinal cords for quantification of expression levels of
inflammasome or other immune genes (Additional file 1:
Table S1; Additional file 2: Figure S2).
RNA sequencing
Tissue was lysed in a MagNA Lyser using TriPure
(Sigma-Aldrich) and MagNA Lyser green beads (Roche).
RNA was isolated using Qiagen QIAcube and quality
check was done with a BioAnalyzer RNA Nano Chip
(Agilent). cDNA synthesis was performed using NuGEN
Ovation RNA-Seq System V2 (7102-A01; NuGEN, San
Carlos, CA, USA) followed by purification with Qiagen
MinElute Kit. DNA was sheared to 200 to 400-bp frag-
ments. The DNA was end polished and dA tailed, and
adaptors with Bioo barcodes were ligated (Life Tech-
nologies). The fragments were amplified (eight cycles)
and quantified with a QuBit (Thermo Fisher Scientific).
Libraries were sequenced using the HiSeq PE cluster kit
v4 (Illumina Inc., San Diego, CA, USA) on the HiSeq
2500 platform (Illumina), resulting in 125-bp reads.
RNA sequencing analysis
Reads were trimmed using Trimmomatic [8] (v0.32) and
subsequently aligned against the mm10 reference gen-
ome using HISAT2 [39] (v2.0.4) applying default param-
eters. Counts were obtained using the Ensembl GRCm38
GTF (v87) with HTSeq [1] (v0.6.1). Quality checks were
performed with FastQC (https://www.bioinformatics.babra-
ham.ac.uk/projects/fastqc/; v0.11.5). The data were analyzed
using Ingenuity Pathway Analysis (IPA; QIAGEN Inc.,
https://www.qiagenbioinformatics.com/products/ingenuity-
pathway-analysis/) [41].
Light and fluorescence microscope
Six micron-thick paraffin sections were cut and collected
on Superfrost Plus glass slides (VWR international, Leu-
ven, Belgium), dried overnight at 37 °C and subsequently
deparaffinized in xylene and rehydrated through a series
of ethanol. Endogenous peroxidase activity was blocked
by incubation in methanol (Merck, Darmstadt, Germany)
with 0.3% H2O2 (Merck) for 20 min at RT. Sections were
then rinsed in PBS and, where appropriate, pretreated
with microwave antigen retrieval (3 min at 900 W
followed by 10 min at 90 W) in either 0.05 M tris buffered
saline (TBS, pH 7.6) or 10 mM citric acid buffer pH 6.0 or
10 mM Tris/1 mM ethylenediaminetetraacetic acid
(EDTA) buffer pH 9.0 (Additional file 1: Table S3).
Following overnight incubation at 4 °C in the appropri-
ate primary antibody (Additional file 1: Table S3) diluted
in Normal Antibody Diluent (Immunologic, Duiven, The
Netherlands), sections were incubated with a donkey anti-
rabbit IgG HRP-linked antibody (diluted 1:1000 in PBS,
Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA, USA) or with a donkey anti-goat IgG HRP-linked
antibody (diluted 1:1000 in PBS, Jackson ImmunoRe-
search Laboratories) or with a donkey anti-mouse IgG
HRP-linked antibody (diluted 1:1000 in PBS, Jackson
ImmunoResearch Laboratories) or with the BrightVision
poly-HRP-anti-rabbit IgG biotin-free (diluted 1:1 in PBS,
Immunologic) for 45 min at RT. Incubation with the Vec-
tor® M.O.M.™ Immunodetection Kit (Vector Laboratories)
was applied where appropriate. The immunostaining was
visualized with 3,3′-diaminobenzidinetetrahydrochloride
dihydrate (DAB, Vector Laboratories, Burlingame, CA,
USA) or with the EnVision detection kit, containing a high
sensitivity DAB chromogenic substrate system (Dako,
Glostrup, Denmark). Sections were then counterstained
with hematoxylin (Sigma-Aldrich) and mounted with Vec-
taMount (Vector Laboratories).
To control for the specificity of the antibodies mouse
spinal cord sections were stained according to the proto-
col described above except for the primary incubation
step, which was omitted. In a second experiment, the
primary antibody was subjected to an adsorption test
using purified protein following an established protocol
[55, 70]. In both cases, no signal was observed.
For fluorescent double immunostaining, primary anti-
bodies (Additional file 1: Table S3) were incubated sim-
ultaneously overnight followed by incubation with the
donkey anti-goat or mouse fluorescein isothiocyanate
(FITC)-conjugated (Sigma-Aldrich) and the donkey anti-
rabbit Cy3-conjugated secondary antibodies (Sigma-Al-
drich) diluted 1:200 in PBS for 45 min at RT. Nuclear
staining was visualized by 4′, 6-diamidino-2-phenylin-
dole, (DAPI, Vector Laboratories) and sections were
mounted in Vectashield (Vector Laboratories).
Images were acquired with a digital camera (DP25;
Olympus, Zoeterwoude, The Netherlands) attached to a
light microscope (Olympus, BX41, The Netherlands) for
colorimetric staining or with a digital camera
(DFC345FX, Olympus, The Netherlands) attached to a
Leica-2 DM IRBE confocal microscope (Leica Microsys-
tems BV, Rijswijk, The Netherlands) for immunofluores-
cent staining. Confocal image stacks were processed
with Leica Application Suite (LAS) AF microscope soft-
ware V2.3.5 (Leica Microsystems BV).
Michailidou et al. Acta Neuropathologica Communications  (2018) 6:36 Page 4 of 17
Electron microscope
After the indicated treatment, the samples were fixed in
Karnovsky’s glutaraldehyde (Polysciences, Inc., Warring-
ton, PA, USA) and post-fixed with 1% osmium tetroxide
(OsO4, Electron microscopy sciences, Hatfield, PA,
USA; in cacodylate buffer). Subsequently, the samples
were dehydrated in an alcohol series and embedded into
Epon (LX-112 resin Ladd research, Williston, VT, USA).
First semi-thin (1 μm) sections were cut for overview
images and stained with Richardson’s staining solution
[13]. Then ultrathin (80 nm) epon sections of the desired
areas were cut and collected on Formvar-coated grids,
counterstained with uranyl acetate and lead citrate. Sec-
tions were examined with a FEI Tecnai-12 G2 Spirit
Biotwin electron microscope (Fei, Eindhoven, The
Netherlands), and images were taken with a Veleta cam-
era using Radius software (EMSIS, Münster, Germany).
Quantification of immunoreactivity
Quantification of synaptophysin (SYP) and C9 reactivity
was performed in the grey matter of stereotactic paraffin
sections obtained from the cervical spinal cord segment.
Quantification of Luxol fast blue (LFB) signal, proteoli-
pid protein (PLP) reactivity or ionized calcium-binding
adapter molecule 1 (IBA-1) reactivity was performed in
paraffin sections obtained from the cervical or the thor-
acic spinal cord segment. Briefly, non-overlapping im-
ages covering > 95% of the area of interest were acquired
from healthy control, no drug and C6 antisense-treated
mice (8–10 images/section, 3 sections/mouse, 3–6 mice/
group), at a 20× magnification using an Olympus BX41
microscope (Olympus), and processed with the Cell-D
software (Olympus). Quantitative analysis of immuno-
staining was performed using the ‘measurement’ func-
tion of the Image J software (Image Pro Plus 5.1,
National Institutes of Health, Bethesda, USA). Briefly,
for each picture, the immunoreactive area was measured
and divided to the total area of measurement. For meas-
urement of the immunoreactive area a threshold was set
and applied to all images in the same staining group.
The percentage of immunoreactive area over the total
area assessed was then calculated for each section. Aver-
age measurements per mouse were finally plotted for
each group. Data were represented as mean ± SEM.
Quantification of axonal damage
Quantification of axonal damage was performed in the
ventrolateral column of Richardson-stained epoxy resin
sections obtained from the cervical and thoracic spinal
cord segments. Non-overlapping images covering > 95%
of the ventrolateral column were acquired from the C4
and T4 level of healthy control, no drug and C6
antisense-treated mice (10–12 images/section, 2 sec-
tions/mouse, 4–6 mice/group). Images were captured at
a 100× magnification using a Olympus BX41 microscope
(Olympus). All animals were analyzed in a blinded fash-
ion by two individual observers. Quantification of the
damaged axons was performed using the Image J soft-
ware (Image Pro Plus 5.1, National Institutes of Health,
Bethesda, USA). Briefly, for each section an approximate
number of 1000 axons was counted manually, using the
‘Cell Counter’ option of the ‘Plugins’ function. A second
counter was then used for the quantification of damaged
axons only. The percentage of damaged axons over the
total number of counted axons was then calculated for
each section. Damaged axons showed signs of demyelin-
ation and/or degeneration. Data were represented as
mean ± SEM.
Statistical analysis
Statistical tests were performed using Prism software
(v7; GraphPad software, San Diego, CA, USA). The vari-
able distribution was assessed by the Shapiro-Wilk test.
When the test distribution was not normal, a non-
parametric Kruskal–Wallis test was used followed by a
Dunn’s multiple comparison test to assess intergroup
differences. When the test distribution was normal, a
One-Way Analysis of Variance (ANOVA) test was ap-
plied followed by Bonferroni correction for multiple
comparisons. Data were represented as a mean ± SEM.
The results were considered significant when p value <
0.05 at a 95% confidence level.
Results
Systemic inhibition of MAC or C5aR1 limits relapse
To study the specific effect of MAC on neuroinflamma-
tion we used an antisense oligonucleotide (5 mg/kg) tar-
geting the mRNA of complement component C6. The
majority of C6 produced in the body is synthesized in
the liver [29] and this oligonucleotide strongly reduces
liver mRNA levels (Additional file 2: Figure S1). By redu-
cing the C6 mRNA levels in the liver the body is de-
pleted of C6 (Additional file 2: Figure S1) and this
prevents MAC assembly. We compared the effect of C6
antisense on clinical scores of mice with chronic relaps-
ing EAE to that of PMX205 (1.5 mg/kg), an antagonist
of C5aR1, thereby blocking C5aR1-mediated inflamma-
tion [47] (Fig. 1a). Unlike the C6 antisense oligonucleo-
tide which cannot permeate the CNS, PMX205 enters
the intact CNS (Additional file 2: Figure S3). Both drugs
were systemically administered. Treatments started after
disease onset, on day 21 p.i., between first disease epi-
sode and first relapse, when T lymphocytes were acti-
vated and disease-related damage was present.
Treatment with the C6 antisense oligonucleotide pre-
vented relapse (clinical scores at day 38 p.i., C6 anti-
sense vs no drug, 0.17 ± 0.16 vs 2.32 ± 0.34, mean ±
SEM, ***p < 0.001) and all the C6 antisense-treated
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mice showed a stable phenotype post-relapse phase
(clinical scores at day 44 p.i., C6 antisense vs no drug,
0.17 ± 0.16 vs 1.41 ± 0.33, mean ± SEM, **p < 0.01). Clin-
ical scores in the PMX205-treated mice were lower but
not significantly different compared to the no drug lit-
termates (day 38 p.i., PMX205 vs no drug, 0.89 ± 0.35
vs 2.32 ± 0.34, mean ± SEM, p = 0.06; day 44 p.i.,
PMX205 vs no drug, 1.00 ± 0.33 vs 1.41 ± 0.33, mean ±
SEM, p > 0.99; Fig. 1b).
To understand the mechanisms responsible for the C6
antisense- and PMX205-mediated effects on chronic re-
lapsing EAE we analyzed the RNA expression profiles of
spinal cords from C6 antisense-treated chronic relapsing
EAE (n = 3) and PMX205-treated chronic relapsing EAE
Fig. 1 MAC inhibitor prevents relapse whereas, inhibitor of C5aR1-mediated inflammation ameliorates disability. Scheme illustrating inhibition of the
terminal complement pathway a. at the level of C5b-C9 (MAC) by antisense targeting of complement C6 mRNA (C6 antisense, 5 mg/kg), b. at the level of
C5aR-mediated inflammation by an antagonist of C5aR1 (PMX205, 1.5 mg/kg) (a). Clinical scores of mice with chronic relapsing EAE receiving C6 antisense
(n= 13, in red) or PMX205 (n= 10, in green) or no drug (n= 17, in blue). The C6 antisense-treated mice did not show relapse or neurological deterioration
post-relapse phase. In contrast, PMX205 did not stop progression of neurological disability completely. Differences between groups were analyzed by using
the Kruskal-Wallis test by ranks. Data represent the average clinical scores (mean) ± SEM. Statistical differences are indicated (**p< 0.01, ****p< 0.0001). RL,
relapse; RM, remission; ns, not significant (b). Heatmap showing Ingenuity Pathway Analysis (IPA) canonical immune pathways induced by EAE and
significantly affected by treatment with the C6 antisense or the PMX205 inhibitor. Pathways are ranked according to the z-score that predicts activation
(orange) /suppression (blue). PMX205 is a less efficient inhibitor of neuroinflammation compared with the C6 antisense. Data were obtained from RNA-seq
of mouse spinal cords collected at relapse (3 mice/group) (c)
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(n = 3) at relapse, at the point where there was the lar-
gest difference in clinical severity (day 38 p.i), and com-
pared them with cords from no drug chronic relapsing
EAE (n = 3) mice or cords from healthy controls (n = 3)
to perform pathway analysis using IPA [41]. Focusing on
canonical pathways we found that key inflammatory
pathways were activated in the no drug mice when com-
pared to healthy controls (colored orange, z-score > 0),
while these pathways were partially activated or not al-
tered (blank, z-score = 0) in the two treatment groups.
Interestingly, the Tec kinase signaling was slightly down-
regulated in the C6 antisense-treated mice, but upregu-
lated in the PMX205-treated mice. Comparison between
each of the two treatments with the no drug mice
showed a general downregulation of neuroinflammation-
related pathways (colored blue, z-score < 0). Notably,
PMX205 is a less efficient inhibitor of neuroinflammation
compared with the C6 antisense. Moreover, two anti-
inflammatory pathways, the peroxisome proliferator-
activated receptor (PPAR) and the liver X receptor/retin-
oid X receptor (LXR/RXR) pathway, were downregulated
in the no drug mice, but upregulated after treatment with
the C6 antisense. Treatment with the PMX205 activated
only the PPAR pathway, not the LXR/RXR pathway
(Fig. 1c). This suggests that the treatments not only
reduce inflammation but also specifically affect in-
flammation inhibitory pathways.
Systemic MAC inhibition prevents upregulation of NLRP3
components in contrast to C5aR1 inhibition
Previous studies have shown that MAC activates the
inflammasome [45, 78], initiating signaling pathways that
drive inflammatory responses as shown for endothelial cells
[38] and fibroblasts [80]. Activation of the inflammasome is
critical for the induction of EAE since mice deficient in
various inflammasome components are at least partially, re-
sistant to the disease [19, 22, 28, 31–33, 36, 67, 74].
Analysis of RNA-seq data from spinal cords collected at
relapse (day 38 p.i) showed that MAC-induced inflamma-
some activation occurred in chronic relapsing EAE. We
found that the no drug mice showed upregulation of most
genes related to the NLRP3 inflammasome pathway; in
contrast, the C6 antisense-treated mice had no NLRP3
inflammasome gene expression. The PMX205-treated
mice had reduced inflammasome gene expression com-
pared to no drug mice, but still showed higher expression
levels of genes linked to the NLRP3 inflammasome com-
pared to the controls (Fig. 2a-c; for log fold change values
of genes see Additional file 1: Table S4).
Because inflammasome activation leads to cleavage of
the precursor pro-IL-1β and release of the pro-
inflammatory cytokine IL-1β [24] we performed immu-
nostaining for IL-1β/pro-IL-1β on paraffin-embedded
spinal cord tissue from C6 antisense-treated (n = 4),
PMX205-treated (n = 3), and no drug (n = 4) mice, col-
lected at relapse (day 38 p.i.). In line with our RNA-seq
data, we found strong IL-1β/pro-IL-1β reactivity in the
no drug mice, on glial cells, and sparse IL-1β/pro-IL-1β
reactivity in the PMX205-treated mice. No IL-1β/pro-
IL-1β immunoreactivity was ever observed in any of the
C6 antisense-treated mice examined (Fig. 3a-e).
Systemic MAC inhibition protects from axonal and
synaptic damage
Since the C6 antisense MAC-blocking treatment has a pro-
tective effect on chronic relapsing EAE, we studied the role
of MAC on the pathology of the mouse spinal cord. To this
end, formalin-fixed, paraffin embedded spinal cord tissue,
collected post-relapse (day 44 p.i.) from no drug chronic re-
lapsing EAE (n = 4), C6 antisense-treated chronic relapsing
EAE (n = 6) or healthy control (n = 6) mice was analyzed. As
expected, the no drug mice had severe lesions within the
ventrolateral columns. Lesions were demyelinated as they
showed loss of LFB (Fig. 4a, c) and PLP signal (Fig. 4d, f ),
and inflammatory as they showed abundant eosinophilic
cell infiltrates, CD3+ lymphocytes within the meninges
(Additional file 2: Figure S4), and strong reactivity for
IBA-1, a marker of microglia/macrophages (Fig. 4g, j). Im-
munostaining for C9, a marker for MAC deposition,
revealed abundant reactivity within the ventral horns
(Fig. 4k, l, n), the areas composed of motor neurons,
suggesting a link between MAC and motor disability.
In contrast, none of the C6 antisense-treated mice had
demyelinated lesions (Fig. 4b, e). Quantification of LFB
and PLP signal showed a trend towards decrease in the
C6 antisense-treated mice compared to controls which
is likely a result of acute disease (Fig. 4c, f ). All the C6
antisense-treated mice showed IBA-1+ microglia of a
resting morphology (Fig. 4h, i), amounts of IBA-1 reactiv-
ity similar to those found in controls (Fig. 4j) and lack of
CD3+ lymphocytes in the parenchyma or the meninges
(Additional file 2: Figure S4). Reactivity for C9 was sparse
(Fig. 4m), consistent with a drastic reduction of MAC for-
mation by the C6 antisense (~ 70%, ***p < 0.001; Fig. 4n).
Next, we quantified axonal damage on osmium-fixed,
epon-embedded spinal cord tissue, collected post-relapse
(day 44 p.i.) from no drug chronic relapsing EAE (n = 4),
C6 antisense-treated chronic relapsing EAE (n = 6) or
healthy control (n = 6) mice. We report that all the no
drug mice showed wide zones of axonal damage corre-
sponding to the lesioned areas (Fig. 5a). Electron micros-
copy demonstrated various types of axonal damage that
we detected and quantified; 1: destruction of the myelin
sheath, 2: deformation of the myelin sheath with gaps
between tangent layers, 3: infoldings of the myelin sheath
within the axoplasmic area, and 4: onion bulbs (Fig. 5b).
In contrast, the C6 antisense-treated mice examined had
only a few damaged axons (arrows in Fig. 5c, d and arrows
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in Fig. 5e) and an average percentage of axonal damage
that was significantly smaller than that found in the no
drug littermates (C6 antisense vs no drug, 4.23 ± 0.44 vs
31.56 ± 2.67, mean ± SEM, ***p < 0.001; Fig. 5f). Control
mice contained intact axons only (Fig. 5g, h).
Finally, we quantified the number of synapses and
neurons in the grey matter of stereotactic sections of
formalin-fixed spinal cords collected post-relapse (day
44 p.i.) from no drug chronic relapsing EAE (n = 4), C6
antisense-treated chronic relapsing EAE (n = 6) or
healthy control (n = 6) mice. All the C6 antisense-treated
mice showed higher levels of reactivity for SYP, a marker
of synapses, compared with the no drug mice (C6 anti-
sense vs no drug, 66.59 ± 3.49 vs 55.75 ± 2.06, mean ±
Fig. 2 MAC inhibitor completely blocks NLRP3 inflammasome components while, in contrast, C5aR1 inhibition only partially decreases expression.
The inflammasome pathway was modeled by Ingenuity Pathway Analysis (IPA) after analyses of gene expression data from mouse spinal cords
collected at relapse (3 mice/group). Genes showing higher expression levels in the first compared to the second group of each comparison are
colored red. The grey color indicates no changes of expression levels. Note that genes linked to NLRP3 inflammasome activation show no
changes of expression levels in the C6 antisense group (MAC inhibitor, genes colored grey), but increased levels in the PMX205 group (inhibitor
of C5aR1-mediated inflammation, genes colored red) when compared with healthy controls at relapse (a-c). Log fold change values of genes are
shown in Additional file 1: Table S4
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SEM, *p < 0.05). Comparison with the controls indicated
that the no drug mice had an average 23% decrease of
SYP+ punctae (no drug vs control, 55.75 ± 2.06 vs 79.00
± 2.60, mean ± SEM, ***p < 0.001), while in contrast, the
C6 antisense-treated mice had a smaller 12% decrease
(C6 antisense vs control, 66.59 ± 3.49 vs 79.00 ± 2.60,
mean ± SEM, *p < 0.05) (Fig. 6a). Neuron counts showed
no significant differences between the groups (data not
shown), suggesting that any loss of SYP reactivity was
not related to neuronal loss. Correlation analysis indi-
cated a significant negative correlation between C9 and
SYP (coefficient, r = − 0.74, ***p < 0.0001) (Fig. 6b), sup-
porting a link between MAC deposition and synaptic
changes. Histological examination of the ventral horns
of no drug mice showed a punctate staining pattern for
C9, indicative of a synaptic localization (Fig. 6d) that
was further confirmed by the co-localization of the C9
and SYP markers (Additional file 2: Figure S5). Notably,
deposition of C9 within the ventral horns of no drug
mice was associated with the presence of abundant
microglia or macrophages (Fig. 6e) and NLRP3 immuno-
reactivity (Additional file 2: Figure S6). Examination of
the ventral horns of C6 antisense-treated mice showed
abundant SYP+ punctae, few microglia of a resting
phenotype and absence of NLRP3 reactivity (Fig. 6f-h
and Additional file 2: Figure S6).
Discussion
This study demonstrates that systemic knockdown of
complement C6 mRNA, when applied after the disease in-
duction, prevents relapse in chronic relapsing EAE. Inhib-
ition of MAC formation is the most likely mechanism of
action of the C6 antisense oligonucleotide. Reduced
amounts of MAC in the CNS are associated with lack of
activation of local parenchymal inflammatory pathways
known to induce or maintain neuroinflammation, such as
the NLRP3 inflammasome. Protection against clinical dis-
ability conferred by MAC inhibition is exerted through
the prevention of axonal and synaptic damage. Overall,
these data suggest that even in the presence of activated T
lymphocytes, MAC is a key contributor to neuroinflam-
mation driving degeneration. Inhibition of C5aR1-
mediated inflammation also affected disease severity but
only ameliorated progressive neurological disability.
The complement system, a major component of innate
immunity, is a sensor of immune homeostasis and a versa-
tile effector of host defense. The classical pathway of com-
plement activation involves recognition of pathogen- or
danger-associated molecular patterns by C1q, induction of
pro-inflammatory responses by cleaved C3 and C5, and
elimination of targeted cells by MAC. While complement
proteins are rapidly recruited to protect the human body
against intruders, this pathway may also transform to an
unwanted self-attacking mechanism that perpetuates in-
jury if uncontrolled [66].
Because of the central role of complement in immun-
ity, the interest in anti-complement therapeutics has in-
creased over the last decades. Multiple agents targeting
different components of the complement system have
been developed [57]. The terminal pathway of comple-
ment is undoubtedly an interesting signaling branch for
intervention. Inhibition at this level prevents potentially
deleterious inflammatory responses without affecting up-
stream complement functions that are beneficial [75].
Eculizumab (Soliris; Alexion Pharmaceuticals) is an in-
hibitor of the C5 component and the only terminal
pathway-specific drug that has so far received approval
for clinical use. Soliris is prescribed in patients with
Fig. 3 MAC inhibitor completely inhibits IL-1β synthesis while, in contrast, C5aR1 inhibition only partially decreases expression. Immunostaining
for interleukin 1 beta (IL-1β)/pro-IL-1β, indicator of NLRP3 inflammasome activation, shows reactivity within the spinal cord of no drug mice (n =
4, arrows in a), on cells with a glial morphology (a, b). IL-1β/pro-IL-1β was never detected in the cords of C6 antisense-treated mice (n = 4) (c),
while PMX205-treated mice showed sparse reactivity (n = 3) (arrows in d, e). Tissue was collected at relapse. Scale bars (a, c, d) 25 μm, (b, e)
5 μm. Hematoxylin was used as counterstain in (a-e)
Michailidou et al. Acta Neuropathologica Communications  (2018) 6:36 Page 9 of 17
paroxysmal nocturnal hemoglobinuria (PNH) or atyp-
ical hemolytic uremic syndrome (aHUS) [27, 84] and is
currently undergoing phase III of a clinical trial for the
prevention of neuromyelitis optica (NMO) relapses
(https://clinicaltrials.gov/ct2/show/NCT01892345). It
targets C5, blocking both MAC assembly and the for-
mation of C5a [27, 84].
MAC is the end product of complement activation
and the most inflammatory component of the terminal
complement pathway [66]. Lytic levels of MAC can dir-
ectly destroy infected or damaged cells, by disrupting
plasma membranes, which are then cleared by recruited
phagocytes [20, 30]. Moreover, sub-lytic amounts of
MAC can trigger the activation of NLRP3 inflammasome
Fig. 4 C6 antisense-mediated MAC inhibition prevents demyelination and microglia/macrophage activation in chronic relapsing EAE. Histological analysis
of semi-serial paraffin sections of the mouse cervical spinal cord segment showed lesions in the no drug mice (n= 4) but no signs of active disease in the
C6 antisense-treated mice (n= 6). Tissue was collected post-relapse phase. Staining for Luxol fast blue (LFB) and quantification of the signal (a-c) as well as
staining for proteolipid protein (PLP) and quantification of the reactivity (d-f) indicated demyelination in the no drug mice (demyelinated lesions pointed
by arrows in a and d), but no significant myelin loss in the C6 antisense-treated mice (c, f). Immunostaining for ionized calcium-binding adapter molecule
1 (IBA-1) (g-j) revealed microglia/macrophages within the lesions (arrows in g) and at the peri-lesional area of the no drug mice with a morphology
consistent with an activated status. In contrast, all the C6 antisense-treated mice showed amounts of IBA-1+ reactivity similar to the ones found in controls
and morphology of IBA-1+ microglia consistent with a resting status (h-j). Moreover, the no drug mice had abundant reactivity for C9, a marker of MAC
deposition, within the ventral horns of the spinal cord. In contrast, the C6 antisense-treated mice showed only small amounts of MAC (k-n). Scale bars:
(a, b, d, e, g, h, k, m) 200 μm, (i, l) 50 μm. Cresyl violet (CV) was used as counterstain in (a, b). Hematoxylin was used as counterstain in (d, e, g-i, k-m)
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in the target cells, promoting clinical disease and primary
or secondary tissue damage [45, 78].
On the other hand, C5a is known to have both pro-and
anti-inflammatory properties depending on the receptor-
ligand interaction and disease studied [9, 47]. More specif-
ically, C5a can bind to one of the two competing recep-
tors, C5aR1 (CD88) and C5aR2 (C5L2), and the balance in
C5a occupancy determines whether the response is pro-
or anti-inflammatory [81, 87]. Pro-inflammatory responses
include G-protein-dependent cell signaling leading to
intracellular Ca+ 2 production, chemotaxis and oxidative
stress. Anti-inflammatory responses include non G-
protein-dependent signaling that alters pro-inflammatory
cytokine production, limiting inflammation [46, 81].
Fig. 5 C6 antisense-mediated MAC inhibition protects from axonal damage. Richardson’s staining on spinal cord tissue from no drug mice
showed wide areas of axonal damage corresponding to the lesioned areas (a). Electron microscopy micrograph indicates the types of axonal
damage detected and quantified: 1. destruction of the myelin sheathe, 2. deformation of the myelin sheathe with gaps between tangent layers,
3. infoldings of the myelin sheathe within the axoplasmic area, and 4. onion bulbs (b). Picture of Richardson’s stained spinal cord section and
electron microscopy micrograph from C6 antisense-treated mice (c-e) showing rarely detected damaged axons (arrows in c, d and arrows in e).
Graph shows the percentage of axonal damage as quantified in the ventral and lateral column of the cervical and thoracic spinal cord segments
from control (n = 6), no drug (n = 4) or C6 antisense-treated (n = 6) mice, collected post-relapse. Comparisons between groups were performed
using the Kruskal-Wallis test by ranks. Data are expressed as the average (mean) ± SEM. Statistical differences are indicated (***p < 0.001) (f).
Pictures from control mice showed intact axons only (g, h). Scale bars: (a, c, g) 25 μm, (b, e) 2 μm, (d) 500 nm (h) 200 nm
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Thus far, there is no complete understanding of the role of
the terminal complement pathway on neuroinflammation. A
number of studies showing deletion or pharmacological
inhibition of complement components, related frag-
ments or complement receptors have been published
reporting controversies. More specifically, deficiency or
blockade of C5a receptors failed to protect against
acute EAE, while expression of C5a in the brain did not
exacerbate EAE [56, 64, 65]. Moreover, deficiency of C5
reduced remyelination in chronic EAE possibly due to an
Fig. 6 C6 antisense-mediated MAC inhibition protects from synaptic alterations. Quantification of synaptophysin (SYP) positive punctae
showed a significant decrease of synaptic densities (*p < 0.05) in the no drug (n = 4) compared to the C6 antisense-treated mice (n = 6),
post-relapse phase. Differences between groups were analyzed by using the One-Way Analysis of Variance test. Data are expressed as the
average (mean) ± SEM. Statistical differences are indicated (*p < 0.05, ***p < 0.001). Controls are healthy mice injected with adjuvant only
(n = 6) (a). Pearson’s correlation coefficient showed a significant negative correlation between SYP and the C9 marker of MAC (coefficient,
r = – 0.74, ***p < 0.0001), in the mouse spinal cord (n = 29 corresponding fields plotted) (b). Histological analysis of paraffin spinal cord
sections from no drug mice showed low densities of SYP+ punctae (arrow pointing to a synapse), sign of synaptic alterations or loss (c),
abundant C9 reactivity (arrows) (d), and ionized calcium-binding adapter molecule 1 (IBA-1) positive microglia/macrophages with a
morphology consistent with an activated status (e). In contrast, histological analysis of spinal cords from C6 antisense-treated mice
showed abundant SYP+ punctae (arrows) (f), sparse C9 reactivity (arrows) (g), and IBA-1+ microglia with a morphology consistent with a
resting status (h). Scale bars: (c-h) 10 μm. Hematoxylin was used as counterstain in (c-h)
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effect of MAC on oligodendrocyte apoptosis [58, 83]. In
contrast, deficiency of C6 in a rat model of acute EAE pro-
tected against demyelination and immune cell infiltration
[51, 77]. Notably, reconstitution of C6 in these rats re-
stored EAE [51].
In this study, we aimed to define the role of MAC on
neuroinflammation by delineating its effect from that in-
duced by C5aR1, and compare the effect of a MAC in-
hibitor, being a knockdown of C6, to that of a C5aR1
antagonist. We found that systemic administration of
the MAC inhibitor after disease onset prevented relapse
in mice with chronic relapsing EAE by suppressing key
pro-inflammatory pathways within the CNS. In contrast,
administration of the C5aR1 antagonist only mitigated
neurological disability.
Which factor determines the molecular and/or clinical
differences between the two treatment groups? Expres-
sion profiling of the spinal cords of the chronic relapsing
EAE animals shows that C6 inhibition has a major effect
on the NLRP3 inflammasome pathway. The NLRP3
inflammasome is a multiprotein complex abundantly
expressed in the CNS that is activated by a wide range
of endogenous or exogenous signals to potentiate neu-
roinflammatory responses with the release of IL-1β and
IL-18 [79]. Activation of the inflammasome was previ-
ously linked to MAC deposition [45, 78]. MAC precur-
sor proteins can leak into the CNS during transient
openings of the blood–spinal cord barrier (BSCB) caused
by immunization with spinal cord antigens in the
chronic relapsing EAE model [71]. Our RNA-seq data
demonstrated that the NLRP3 inflammasome pathways
are ‘switched on’ in the no drug and the C5aR1-inhibited
mice, but not in the MAC-inhibited mice in comparison
with controls. Moreover, pathway analysis with IPA
showed that the Tec kinase signaling, a regulator of the
NLRP3 inflammasome [34], was upregulated in the
C5aR1-inhibited mice, but not in the MAC-inhibited lit-
termates. These data were consistent with our finding
that all the no drug and the C5aR1-inhibited mice
showed IL-1β/pro-IL-1β + glial cells while, none of the
C6 antisense-treated mice showed any IL-1β/pro-IL-1β
immunostaining. Our data confirm previous reports of a
specific effect of MAC on the activation of NLRP3
inflammasome [45, 78] and further suggest that MAC
formation stimulates immune responses in glial cells to
initiate or boost neuroinflammation in this model.
Indeed, examination of spinal cords from no drug mice
showed MAC deposition associated with abundant micro-
glia/macrophages, sign of local immune reaction to MAC.
MAC was deposited on synapses and its reactivity was
negatively correlated to synaptic densities. In contrast,
spinal cords of MAC-inhibited mice showed a few micro-
glia of a resting phenotype and higher synaptic densities.
These data together with our observation that MAC
deposits are restricted to the ventral horns, the area of
motor neurons, and are linked to local NLRP3 expression
suggest a link between MAC, accumulation and/or activa-
tion of microglia and neurological disability in chronic re-
lapsing EAE. It is possible that deposition of MAC on
synapses leads to synaptic damage due to pore formation.
Pores may in turn, promote the release of ATP [59], an
important messenger that can be sensed by the neighbor-
ing glia via the purinoceptor 7 (P2X7) receptor [49], to in-
duce bystander NLRP3 inflammasome activation for
release of IL-1β. IL-1β can then exacerbate disease by trig-
gering the opening of the BSCB and promoting the infil-
tration of immune cells in the CNS [73].
Once peripheral immune cells enter the CNS paren-
chyma, complement can regulate their differentiation, in the
case of lymphocytes [2, 12], or promote their activation by
the release of anaphylatoxins, in the case of macrophages or
neutrophils [25]. Activated immune cells are important me-
diators of neuroinflammation and lesion formation. Import-
antly, we found only a few immune cells, no demyelinated
lesions and a small number of damaged axons in all the
MAC-inhibited mice tested while, in contrast, all the no
drug mice showed demyelinated lesions with abundant cell
infiltrates and damaged axons. These data are in line with
our previous finding that MAC inhibition reduces the num-
bers of infiltrating macrophages, impeding degeneration in
the CNS after brain trauma [17, 69]. In addition, C6 defi-
cient rats (rats genetically unable to form MAC) showed re-
duced numbers of CD68+ and CD11b + cells at the site of
injury after crush nerve injury [63].
Comparison of RNA-seq data from MAC-inhibited
mice to those from no drug mice showed activation of
two important anti-inflammatory pathways, the PPAR and
the LXR/RXR pathway [15, 37, 76]. It is known that the
C6 antisense oligonucleotide does not penetrate the CNS.
Therefore, we speculate that activation of these protective
mechanisms in the MAC-inhibited mice might be an
intra-parenchymal response that is related either to block-
ade of immune cell infiltration or to another unknown
function of the C6 antisense oligonucleotide. In contrast,
the C5aR1-inhibited mice showed activation of the PPAR
pathway only. This is an interesting observation since the
C5aR1 antagonist enters the CNS and may therefore act
both in the periphery and the CNS.
MAC has been involved in the pathology of a wide range
of acute and chronic neuroinflammatory diseases. Acute
multiple sclerosis, stroke, traumatic brain injury (TBI) and
NMO are major examples of acute or recurrent neuroin-
flammatory brain conditions in which MAC may have an
important pathological contribution [6, 17, 48, 54]. More-
over, MAC, detected by an antibody against a neo-epitope
in C9 (C9neo), was found in brains from donors with the
chronic course of multiple sclerosis, in the absence of ful-
minate inflammation [82], in Alzheimer’s disease brains on
Michailidou et al. Acta Neuropathologica Communications  (2018) 6:36 Page 13 of 17
senile plaques [50, 55], and in amyotrophic lateral sclerosis
(ALS) brains on still innervated motor endplates, suggest-
ing a role as a modifier of disease progression [3]. Although
chronic diseases are far less inflammatory than acute, their
pathology does include inflammatory responses, but of a
type different than the acute ones, and this might explain
the failure of current treatments to halt disease progression
[42]. Our finding in mice that MAC is linked to NLRP3
inflammasome activation and IL-1β production might have
implications for the diagnosis and therapy of
neuroinflammation-related diseases in humans, especially
in the view of accumulating evidence pointing towards a
pathogenic role of IL-1β. IL-1β transcript or protein was
detected in the cerebrospinal fluid, blood or lesions of pa-
tients with multiple sclerosis [11, 26, 60] and was linked to
the extent of cortical demyelination or to disease severity
[68, 72]. Interestingly, treatment of multiple sclerosis pa-
tients with the FDA-approved therapeutic agents type-I
IFN, glatiramer acetate or natalizumab (https://www.ncbi.
nlm.nih.gov/books/NBK294198/table/introduction.t1/#__N
BK294198_dtls__) was shown to affect the expression of
IL-1Ra and/or the production of IL-1β [10, 23, 52, 53].
Complement inhibition, as with most immunomodula-
tory interventions, weakens the immune responses to
pathogens, which over time, can lead to recurrent and/or
severe infections in patients. Although activation of up-
stream complement functions suffices for protection
against most infective organisms, there is one group of
bacteria, the Neisseria species, which requires activation
of the terminal pathway [16]. Neisseria meningitides infec-
tion leads to meningococcal sepsis or meningitis. Individ-
uals deficient in C5 or terminal pathway components have
a higher susceptibility for Neisseria meningitides infec-
tions. However, not all deficiencies might have similar
increased risks. C6 and C7 deficiencies could be less
severe [86]. For prevention of meningococcal disease it is
recommended that patients receiving Soliris receive
prophylactic antibiotics and are vaccinated against all
meningococcal strains [18]. It remains to be demonstrated
whether treatment with a C6 inhibitor will cause less risk
of meningococcal infections due to the extra anti-
microbial protection provided by the C5a-related anaphyl-
actic mechanism. Therapeutic anti-C6 antibodies are now
under development and in a preclinical stage [57]. These
antibodies may serve to circumvent problems related to
blockade of C5a-mediated inflammation.
In this study, we also show that PMX205, a C5aR1 in-
hibitor ameliorates disability but does not completely
prevent the relapse in chronic relapsing EAE. An explan-
ation for this difference is that MAC is a more potent
pro-inflammatory molecule in this model than C5a. In
addition, C5a does not have only pro-inflammatory but
it also has anti-inflammatory properties [9]. Compared
to the no drug mice, there is a clear effect of PMX205
however. The severity of the relapse was less. Expression
profiling showed reduced expression of inflammatory
pathways regulating relapse in chronic relapsing EAE.
However, activation of the NLRP3 inflammasome, as
measured by expression levels of related genes and by
IL-1β/pro-IL-1β + glial cells, was moderately affected. It
is therefore likely that MAC predominantly drives this
effect in this model.
A limitation of this study is the lack of data related to
the contribution of the two tested inhibitors on the
mouse peripheral cell immunity. Further research is re-
quired to address impact on immune cells peripherally
and in the CNS. Our findings add to previous reports of
a link between the terminal complement pathway and
inflammasome activation. In this study we further dem-
onstrate that MAC is a major player in neuroinflamma-
tion that drives spinal cord degeneration, providing a
rationale for the use of complement-targeting therapies
to combat chronic neuroinflammatory diseases.
Conclusions
Our research demonstrates that inhibition of the terminal
complement pathway at the symptomatic disease phase
effectively stops neuroinflammation in the chronic relaps-
ing EAE model. This is the first study that delineates the
specific roles of C5a receptor signaling and MAC forma-
tion in vivo using selective inhibitors. Our finding that sys-
temic inhibition of MAC prevented relapse completely in
mice whereas, inhibition of the C5aR1 mitigated neuro-
logical disability reveals a key role for MAC in neuroin-
flammation driving degeneration. This study might
represent a first step towards pre-clinical development of
MAC inhibition as therapy for chronic neuroinflammatory
diseases like multiple sclerosis.
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